18 October 2022

Manager of Company Announcements
Australian Securities Exchange
Exchange Centre
Level 3
20 Bridge Street
Sydney NSW 2000

Dear Sir/Madam,

Proposed Issue of Securities to Chief Executive Officer

In accordance with Listing Rule 3.10.3, Pharmaxis advises that the directors have resolved to grant performance rights to the Chief Executive Officer under the Company's employee incentive scheme. The grant requires shareholder approval which will be sought at the annual general meeting of the Company:

Class of security	Unlisted zero grant and zero exercise price employee options over Pharmaxis Ltd ordinary shares.
Number to be issued	2,771,000
Issue price	Nil
Exercise price	Nil
Vesting	1. 50% of the performance rights will vest at each of 30 June 2024 and 30 June 2025, provided that Mr Phillips is an employee at these times.
Conditions applicable to the shares issued on exercise of Performance Rights	2. Any shares acquired upon exercise of Performance Rights vesting on 30 June 2024 may not be traded until 30 June 2025, and only then with prior approval of the Pharmaxis Board. 3. Any shares acquired upon exercise of Performance Rights vesting on 30 June 2025 may only be traded with prior approval of the Pharmaxis Board.
Shareholder approval	Shareholder approval will be sought at the 2022 Annual Meeting.
Purpose of issue	To be issued to the Chief Executive Officer under, and in accordance with, the Pharmaxis employee incentive scheme for the long term reward, incentive and retention of senior managers and other key employees.
Issue to class	No

The Company will lodge the relevant Appendix 3G when required by the Listing Rules of Australian Securities Exchange. Further detail concerning Pharmaxis' use of Performance Rights are set out in the 2022 Directors' Report and Remuneration Report filed with the Australian Securities Exchange on 30 August 2022.

Sincerely,

David McGarvey
Company Secretary